COVID-19 ACIP Vaccine Recommendations
Advisory Committee on Immunization Practices (ACIP)
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT COVID-19 Vaccine Recommendations
- MMWR: November 11, 2022/ 71(45); 1436-1441
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)- See also:
- MMWR: August 4, 2022/ 71(31); 988-992
Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Novavax COVID-19 Vaccine (cdc.gov)
- ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine, Adjuvanted in adults ages 18 years and older under an Emergency Use Authorization (cdc.gov)
- The Novavax COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events (cdc.gov)
- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6–11 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Persons Aged 12-17 Years
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 – 11 years and Adolescents Ages 12 – 17 years under an Emergency Use Authorization
- MMWR; June 28, 2022/ 71(26)
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022- See also:
- GRADE: Moderna COVID-19 Vaccine for Children Aged 6 Months–5 Years | CDC
- GRADE: Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 Years | CDC
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 Months – 5 Years and Pfizer-BioNTech COVID-19 Vaccine in Children Ages 6 Months – 4 Years under an Emergency Use Authorization | CDC
- Moderna COVID-19 Vaccine’s Reactions and Adverse Events | CDC
- Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events | CDC
- See also:
- EtR Update for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
- EtR Framework for a 2nd COVID-19 Booster Dose in Adults Ages 50 Years and Older and Immunocompromised Individuals
- MMWR; March 17, 2022; 71(11)
Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022 - MMWR; January 21, 2022; 71
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021 - MMWR; November 5, 2021;70
Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Print version [5 pages] - MMWR; November 5, 2021;70
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Print version [8 pages]- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses
- ACIP Evidence to Recommendations for Use of an Additional COVID-19 Vaccine Dose in Immunocompromised People
- ACIP Evidence to Recommendations for Use of COVID-19 Vaccine Booster Doses
- See also:
- MMWR; September 24, 2021;70
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Print version [5 pages] - MMWR; August 13, 2021;70
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version [6 pages] - MMWR; July 9, 2021;70
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version [6 pages] - MMWR; May 14, 2021;70
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version [4 pages]- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 Years
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization
- Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine
- See also:
- MMWR; April 30, 2021;70
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021- See also:
- MMWR; March 2, 2021;70
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version [4 pages]- See also:
- ACIP Evidence to Recommendations for Use of Janssen COVID-19 Vaccine under an Emergency Use Authorization
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
- Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
- See also:
- MMWR; December 22, 2020;69
The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version [5 pages]
- MMWR; December 20, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version [4 pages]
- MMWR; December 13, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version [3 pages] - MMWR; December 3, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version [3 pages]- See also: